Quture International, Inc. (OTCQB: QUTR) ("Q") the proven and experienced clinical performance and outcome analytics and solutions company in American healthcare, now with global capability, today announced the addition of Ron Truxton of Boston, Massachusetts as the Chief Software Architect (CSA) to Q's Management Team. Extensive expertise and experience with the InterSystems strategic technology platform on which Q's QualOptima product is developed was a key determining factor in this strategic hire. A major milestone in Q's transition to revenue-based operations has now been successfully achieved in anticipation of commercialization and production of its product with intensifying marketing and sales and product installations.
Mr. Truxton was an InterSystems Corporation Sales Engineer from 1998 through 2012, where he provided technical sales assistance in all facets of the InterSystems' product line for its customers. He participated in business and detailed technical discussions at all levels and in all departments of the customer's organization to foster the adoption, use and deployment of InterSystems' technologies giving corporate presentations and demonstrations to InterSystems' customers and prospects at site visits, marketing events and such venues. Topics included strategic and tactical technical and business directions and technical product demonstrations.
Prior to InterSystems, Mr. Truxton was a sales engineer and systems integrator for three other software companies in Massachusetts. Since his employment with InterSystems, he has led Gydder, Inc., a healthcare solutions provider including InterSystems technology, as their contract Business Development Manager. Mr. Truxton holds the Master of Science degree in physics from Tufts University.
"Quture is extraordinarily excited and pleased to retain Ron Truxton," said Landon Feazell, Chairman and CEO. "We jointly believed with InterSystems that having an expert in their tools and sophisticated technology available inside the Company on our Management Team is essential to successful product commercialization and sales. With over 15 years' experience in pre and post-sales support at the C-level and with developers, combined with his excellent business acumen and ability to sell into dynamic markets, we are confident that Ron is the perfect fit for Quture, its vision, subsidiaries, products and services. He will be crucial to the successful commercialization of QualOptima, continued product development, customer support, as well as marketing, sales and product installations plans. Having accomplished this major milestone in our transition to revenue-based operations, Q looks forward to moving full speed ahead with our go-to-market plan."
Q's QualOptima Analytics & Connectivity System is transformative, first to market, disruptive technology to enhance clinical performance to achieve optimal patient outcomes. As the free enterprise solution to improving health and healthcare while reducing costs, Q is positioned through its disruptive technology to become the foremost global provider of value-based clinical intelligence and knowledge solutions.
"Our long-term strategy is to market to additional customer segments to provide the platform and clinical knowledge solutions to empower interchange of information between patients, providers and payers for the changing medical model," said Feazell. "Q's significantly expanded expertise positions us to more rapidly and confidently develop additional products and functionalities for QualOptima to meet the urgent, expanding needs of our customers within the healthcare system. With the power of our technology platform to exchange information through mobile applications, Q is extremely confident in our marketing and technology development strategies for Q's short and long-term future."
Mr. Truxton will work in Boston, coordinating Q's efforts in the Northeast and particularly with the Company's strategic alliances and Application Partnership. His addition facilitates Q's Chief Technology Officer, Sherif Elfayoumy, PhD, to concentrate more in his extraordinary expertise and experience with natural language processing tools focused immediately on machine reading and learning for triggers in narrative text to monitor quality and patient safety. Collaboration of these experts to lead the Q'Zure, LLC technology services to Q will be even more dynamic than previously and facilitate more rapid technology and product development.
About Quture International, Inc.
Quture International (OTCQB: QUTR) is the proven and experienced clinical performance and outcome analytics and solutions company in American healthcare. Q's first-to-market clinical intelligence software is the complete solution for healthcare providers, payers, employers, and insurance companies seeking to achieve optimal clinical, financial and operational outcomes. Q's QualOptima Connectivity & Analytics System empowers value-driven, patient-centered, personalized care focused on real-time and predictive patient management and patient safety, with optimal quality demonstrated by outcomes correlated with resource use, revenue and cost. As an Application Partner of InterSystems Corporation, Q's software operates on their HealthShare strategic technology platform to capture, integrate, aggregate, and analyze data transformed to knowledge in Q's innovative second-generation database. InterSystems (www.intersystems.com) has customers in over 100 countries with 80% of top hospitals in America currently utilizing its technology. Q's core competence and value proposition lies in its embedded evidence-based metrics, clinical content and analytic algorithms developed from over 35 years of measuring performance in hundreds of hospitals, physician organizations and HMOs.
As the free enterprise solution to improving health and healthcare while reducing costs, Q is positioned through its disruptive technology to become the foremost global provider of value-based clinical intelligence and knowledge solutions. Q is a Nevada corporation based in Daytona Beach, Florida, and trades on the OTC exchange under the symbol 'QUTR.'
Forward Looking Statements:
This release contains forward-looking statements, including, without limitation, statements concerning our business and possible or assumed future results of operations. Our actual results could differ materially from those anticipated in the forward-looking statements for many reasons including: our ability to continue as a going concern, adverse economic changes affecting markets we serve; competition in our markets and industry segments; our timing and the profitability of entering new markets; greater than expected costs, customer acceptance of our products or difficulties related to our integration of the businesses we may acquire; and other risks and uncertainties as may be detailed from time to time in our public announcements and SEC filings. Although we believe the expectations reflected in the forward-looking statements are reasonable, they relate only to events as of the date on which the statements are made, and our future results, levels of activity, performance or achievements may not meet these expectations. We do not intend to update any of the forward-looking statements after the date of this document to conform these statements to actual results or to changes in our expectations, except as required by law. There is no assurance that a definitive agreement will be completed.
SOURCE: Quture International, Inc.